NCT07097064View on ClinicalTrials.gov

Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2033

Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
COMBINATION_PRODUCT

standard radiotherapy with chemotherapy

intensity-modulated conformal radiotherapy (IMRT) 50-54 Gy in 25-30 fractions with concomitant Xeloda 800-825 mg/m2 morning and evening 5d/7.

RADIATION

MRI-guided adaptive stereotactic radiotherapy (SMART)

MRI-guided adaptive stereotactic radiotherapy (SMART) 50 Gy / 5 fractions without concomitant chemotherapy.

Trial Locations (17)

11010

Centre Hospitalier Carcassone, Carcassonne

13009

Institut Paoli-Calmettes, Marseille

21079

Centre Georges François Leclerc, Dijon

29200

CHU Brest, Brest

30029

CHU Nîmes, Nîmes

31059

Institut Claudius Regaud, Toulouse

33076

Institut Bergonié, Bordeaux

33604

CHU Bordeaux Haut-Lévêque, Pessac

34298

Institut régional du Cancer de Montpellier, Montpellier

35042

Centre Eugène Marquis, Rennes

59000

Centre Oscar Lambret, Lille

63011

Centre Jean PERRIN, Clermont-Ferrand

64100

Centre d'Oncologie du Pays-Basque, Bayonne

69100

ORLAM, Villeurbanne

75015

Hôpital européen Georges-Pompidou, Paris

75020

Hôpital Tenon AP-HP, Paris

75651

HU Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER